FR3086534B1 - Methode pour traiter une infection par le virus de l'immunodeficience humaine - Google Patents

Methode pour traiter une infection par le virus de l'immunodeficience humaine Download PDF

Info

Publication number
FR3086534B1
FR3086534B1 FR1859054A FR1859054A FR3086534B1 FR 3086534 B1 FR3086534 B1 FR 3086534B1 FR 1859054 A FR1859054 A FR 1859054A FR 1859054 A FR1859054 A FR 1859054A FR 3086534 B1 FR3086534 B1 FR 3086534B1
Authority
FR
France
Prior art keywords
immunodeficiency virus
human immunodeficiency
treating infection
infection
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1859054A
Other languages
English (en)
Other versions
FR3086534A1 (fr
Inventor
Herve Fleury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Herve Fleury Fr
Original Assignee
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Centre Hospitalier Universitaire de Bordeaux, Universite de Bordeaux filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1859054A priority Critical patent/FR3086534B1/fr
Priority to EP19795609.7A priority patent/EP3860649A1/fr
Priority to PCT/FR2019/052308 priority patent/WO2020070427A1/fr
Publication of FR3086534A1 publication Critical patent/FR3086534A1/fr
Application granted granted Critical
Publication of FR3086534B1 publication Critical patent/FR3086534B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention est relative à une composition comprenant plusieurs peptides comprenant des épitopes proviraux et son utilisation pour le traitement d'une infection par le virus de l'immunodéficience humaine.
FR1859054A 2018-10-01 2018-10-01 Methode pour traiter une infection par le virus de l'immunodeficience humaine Active FR3086534B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR1859054A FR3086534B1 (fr) 2018-10-01 2018-10-01 Methode pour traiter une infection par le virus de l'immunodeficience humaine
EP19795609.7A EP3860649A1 (fr) 2018-10-01 2019-09-30 Methode pour traiter une infection par le virus de l'immunodeficience humaine
PCT/FR2019/052308 WO2020070427A1 (fr) 2018-10-01 2019-09-30 Methode pour traiter une infection par le virus de l'immunodeficience humaine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1859054A FR3086534B1 (fr) 2018-10-01 2018-10-01 Methode pour traiter une infection par le virus de l'immunodeficience humaine

Publications (2)

Publication Number Publication Date
FR3086534A1 FR3086534A1 (fr) 2020-04-03
FR3086534B1 true FR3086534B1 (fr) 2020-11-06

Family

ID=65763527

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1859054A Active FR3086534B1 (fr) 2018-10-01 2018-10-01 Methode pour traiter une infection par le virus de l'immunodeficience humaine

Country Status (3)

Country Link
EP (1) EP3860649A1 (fr)
FR (1) FR3086534B1 (fr)
WO (1) WO2020070427A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
FR2771640B1 (fr) * 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
FR2837104B1 (fr) 2002-03-14 2004-08-06 Dev Des Antigenes Combinatoire Utilisation de melange de lipopeptides pour la fabrication de vaccins
WO2005033265A2 (fr) * 2003-04-25 2005-04-14 Epimmune Inc. Constructions multi-epitope optimisees et leurs utilisations
DE602007010127D1 (en) * 2006-06-01 2010-12-09 Statens Seruminstitut Hiv-impfstoff
KR101523391B1 (ko) * 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
EP4079319A1 (fr) * 2011-10-17 2022-10-26 IO Biotech ApS Immunothérapie par pd-l1
EP2745845A1 (fr) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux Procédé de prévention ou de traitement d'une infection par VIH

Also Published As

Publication number Publication date
EP3860649A1 (fr) 2021-08-11
WO2020070427A1 (fr) 2020-04-09
FR3086534A1 (fr) 2020-04-03

Similar Documents

Publication Publication Date Title
EA201891028A1 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
MA31500B1 (fr) Composes chimiques
MA43763B1 (fr) Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs
EA202191133A1 (ru) Сигнатуры интерферона типа i и способы их применения
JP2021505540A5 (fr)
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
MX2024005705A (es) Composiciones de liquidos ionicos.
EA202191283A1 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
EA202192288A1 (ru) Соединения на основе нейрегулина-4 и способы их применения
MD20190018A2 (ro) Compoziţie, în particular o compoziţie farmaceutică preventivă şi curativă pe bază de peroxometalat
MA58889B1 (fr) Traitement de la douleur neuropathique associée à la neuropathie périphérique induite par la chimiothérapie
EA202190888A1 (ru) Пептид для применения в косметике
EA202192454A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
EA201692180A1 (ru) Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
EA202092229A1 (ru) Мутеины cd4 и способы их применения
FR3086534B1 (fr) Methode pour traiter une infection par le virus de l'immunodeficience humaine
EA202192961A1 (ru) Ребамипид для применения в профилактике и/или лечении синуклеинопатий
EA202190590A1 (ru) Соединения и способы лечения грибковых инфекций
FR3100128B1 (fr) Composition pharmaceutique destinée à inhiber l’infectiosité du VIH, à traiter le syndrome d’immunodéficience acquise (SIDA) et ses complications
EA201290852A1 (ru) Комбинированная терапия, включающая антагонист ccr5, ингибитор протеазы вич-1 и фармакокинетический усилитель
EA202191758A1 (ru) Пептиды для лечения и профилактики диабета и связанных с ним заболеваний
EP3999187A4 (fr) Lymphocytes t à longue durée de vie pour le traitement d'une infection par le vih
CY1115541T1 (el) Μεταλλαγμενη πρωτεϊνη τατ ουι για την προληψη ή την θεραπευτικη αντιμετωπιση του αids
EP4084869A4 (fr) Composition et thérapie pour le traitement de réflexes nauséeux
EP3897721A4 (fr) Procédés d'utilisation d'anticorps de butyrophiline pour le traitement d'une infection par le vih

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200403

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

TP Transmission of property

Owner name: HERVE FLEURY, FR

Effective date: 20211102

TQ Partial transmission of property

Owner name: HERVE FLEURY, FR

Effective date: 20211102

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8